Catalyst Fund said Omrix Biopharmaceuticals, one of its portfolio companies, will be brought to market in an IPO, marking the sixth exit for Catalyst from companies it has acquired.
Catalyst bought it shares in Omrix for $1.6 million in February 2005. The fund is currently finishing the closing of its follow-on fund, Catalyst II.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>